27446579|t|A new marker for breast cancer diagnosis, human epididymis protein 4: A preliminary study
27446579|a|Breast cancer is the most frequently diagnosed cancer type in women. Tumor markers have been widely used for assessing the treatment response and early diagnosis of recurrence. Human epididymis protein 4 (HE4) is expressed in ductal carcinoma of the breast tissue; however, its serum levels and their diagnostic and prognostic potential in breast cancer have not been investigated, which was therefore the aim of the present study. The serum levels of HE4 were determined in 36 breast cancer patients, 11 ovarian cancer patients and 16 healthy volunteers. The association between clinicopathological characteristics of breast cancer and serum HE4 levels was investigated. A significant difference in the median serum levels of HE4 was identified between breast cancer patients, ovarian cancer patients and healthy volunteers (P=0.013). The cutoff value for the prediction of breast cancer was determined at >13.24 pmol/l for HE4, with a sensitivity of 61.11%, specificity of 68.75%, positive predictive value of 81.48%, negative predictive value of 44.0% and accuracy of 63.46%. Furthermore, a positive correlation between the serum levels of HE4 and cancer antigen 15-3 was determined (r=0.399, P=0.026). To the best of our knowledge, the present study was the first to determine the diagnostic value of serum HE4 for breast cancer. A significant elevation of serum HE4 levels in patients with breast cancer compared with that in healthy controls was identified. HE4 may serve as a novel biomarker for the diagnosis of breast cancer.
27446579	6	12	marker	T201	C0005516
27446579	17	40	breast cancer diagnosis	T060	C0596224
27446579	42	68	human epididymis protein 4	T116	C2707001
27446579	72	83	preliminary	T079	C0439611
27446579	84	89	study	T062	C2603343
27446579	90	103	Breast cancer	T191	C0678222
27446579	127	136	diagnosed	T033	C0011900
27446579	137	143	cancer	T191	C0006826
27446579	144	148	type	T080	C0332307
27446579	152	157	women	T098	C0043210
27446579	159	172	Tumor markers	T123	C0041365
27446579	199	208	assessing	T058	C0184514
27446579	213	231	treatment response	T201	C0521982
27446579	236	251	early diagnosis	T060	C0596473
27446579	255	265	recurrence	T191	C0920420
27446579	267	293	Human epididymis protein 4	T116	C2707001
27446579	295	298	HE4	T116	C2707001
27446579	303	312	expressed	T045	C1171362
27446579	316	353	ductal carcinoma of the breast tissue	T191	C1527349
27446579	368	373	serum	T031	C0229671
27446579	374	380	levels	T080	C0441889
27446579	391	401	diagnostic	T033	C0011900
27446579	406	416	prognostic	T201	C0420834
27446579	417	426	potential	T080	C3245505
27446579	430	443	breast cancer	T191	C0678222
27446579	458	470	investigated	T169	C1292732
27446579	496	499	aim	T078	C1947946
27446579	507	514	present	T079	C0521116
27446579	515	520	study	T062	C2603343
27446579	526	531	serum	T031	C0229671
27446579	532	538	levels	T080	C0441889
27446579	542	545	HE4	T116	C2707001
27446579	551	561	determined	T059	C1148554
27446579	568	581	breast cancer	T191	C0678222
27446579	582	590	patients	T101	C0030705
27446579	595	609	ovarian cancer	T191	C0029925
27446579	610	618	patients	T101	C0030705
27446579	626	644	healthy volunteers	T098	C1708335
27446579	650	661	association	T080	C0439849
27446579	670	689	clinicopathological	T169	C1521733
27446579	690	705	characteristics	T080	C1521970
27446579	709	722	breast cancer	T191	C0678222
27446579	727	732	serum	T031	C0229671
27446579	733	736	HE4	T116	C2707001
27446579	737	743	levels	T080	C0441889
27446579	748	760	investigated	T169	C1292732
27446579	764	775	significant	T078	C0750502
27446579	776	786	difference	T081	C1705241
27446579	794	800	median	T081	C0876920
27446579	801	806	serum	T031	C0229671
27446579	807	813	levels	T080	C0441889
27446579	817	820	HE4	T116	C2707001
27446579	825	835	identified	T080	C0205396
27446579	844	857	breast cancer	T191	C0678222
27446579	858	866	patients	T101	C0030705
27446579	868	882	ovarian cancer	T191	C0029925
27446579	883	891	patients	T101	C0030705
27446579	896	914	healthy volunteers	T098	C1708335
27446579	930	936	cutoff	T169	C1442160
27446579	937	942	value	T081	C1522609
27446579	951	961	prediction	T078	C0681842
27446579	965	978	breast cancer	T191	C0678222
27446579	983	993	determined	T059	C1148554
27446579	1015	1018	HE4	T116	C2707001
27446579	1027	1038	sensitivity	T081	C1511883
27446579	1050	1061	specificity	T081	C1511884
27446579	1073	1098	positive predictive value	T081	C1514243
27446579	1110	1135	negative predictive value	T081	C1513918
27446579	1149	1157	accuracy	T080	C0598285
27446579	1184	1192	positive	T033	C1446409
27446579	1193	1204	correlation	T080	C1707520
27446579	1217	1222	serum	T031	C0229671
27446579	1223	1229	levels	T080	C0441889
27446579	1233	1236	HE4	T116	C2707001
27446579	1241	1255	cancer antigen	T109,T129	C0003341
27446579	1265	1275	determined	T059	C1148554
27446579	1315	1324	knowledge	T170	C0376554
27446579	1330	1337	present	T079	C0521116
27446579	1338	1343	study	T062	C2603343
27446579	1361	1370	determine	T059	C1148554
27446579	1375	1385	diagnostic	T169	C0348026
27446579	1386	1391	value	T081	C1522609
27446579	1395	1400	serum	T031	C0229671
27446579	1401	1404	HE4	T116	C2707001
27446579	1409	1422	breast cancer	T191	C0678222
27446579	1426	1437	significant	T078	C0750502
27446579	1438	1447	elevation	T082	C0702240
27446579	1451	1456	serum	T031	C0229671
27446579	1457	1460	HE4	T116	C2707001
27446579	1461	1467	levels	T080	C0441889
27446579	1471	1479	patients	T101	C0030705
27446579	1485	1498	breast cancer	T191	C0678222
27446579	1499	1507	compared	T052	C1707455
27446579	1521	1528	healthy	T080	C3898900
27446579	1529	1537	controls	T096	C0009932
27446579	1542	1552	identified	T080	C0205396
27446579	1554	1557	HE4	T116	C2707001
27446579	1579	1588	biomarker	T201	C0005516
27446579	1597	1606	diagnosis	T033	C0011900
27446579	1610	1623	breast cancer	T191	C0678222